BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 16048492)

  • 1. Occurrence of autoantibodies in chronic graft vs. host disease after allogeneic stem cell transplantation.
    Wechalekar A; Cranfield T; Sinclair D; Ganzckowski M
    Clin Lab Haematol; 2005 Aug; 27(4):247-9. PubMed ID: 16048492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of autoantibody expression in allogeneic stem-cell recipients.
    Moon JH; Lee SJ; Kim JG; Chae YS; Kim SN; Kang BW; Suh JS; Lee KS; Sohn SK
    Transplantation; 2009 Jul; 88(2):242-50. PubMed ID: 19623021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery.
    Patriarca F; Skert C; Sperotto A; Zaja F; Falleti E; Mestroni R; Kikic F; Calistri E; Filì C; Geromin A; Cerno M; Fanin R
    Exp Hematol; 2006 Mar; 34(3):389-96. PubMed ID: 16543073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoantibodies in human chronic graft-versus-host disease after hematopoietic cell transplantation.
    Quaranta S; Shulman H; Ahmed A; Shoenfeld Y; Peter J; McDonald GB; Van de Water J; Coppel R; Ostlund C; Worman HJ; Rizzetto M; Tsuneyama K; Nakanuma Y; Ansari A; Locatelli F; Paganin S; Rosina F; Manns M; Gershwin ME
    Clin Immunol; 1999 Apr; 91(1):106-16. PubMed ID: 10219261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Allogeneic hematopoietic stem cell transplantation in patients with chronic myeloid leukemia in the Czech Republic--a retrospective analysis of results in years 1988-2005].
    Faber E; Koza V; Vítek A; Mayer J; Sedlácek P; Zák P; Zapletalová J; Benesová K; Krejcová H; Steinerová K; Maresová I; Cetkovský P
    Vnitr Lek; 2006 Dec; 52(12):1172-80. PubMed ID: 17299910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of human leucocyte antigen mismatch on graft-versus-host disease and graft failure after reduced intensity conditioning allogeneic haematopoietic stem cell transplantation from related donors.
    Teshima T; Matsuo K; Matsue K; Kawano F; Taniguchi S; Hara M; Hatanaka K; Tanimoto M; Harada M; Nakao S; Abe Y; Wake A; Eto T; Takemoto Y; Imamura M; Takahashi S; Ishida Y; Kanda Y; Kasai M; Takaue Y
    Br J Haematol; 2005 Aug; 130(4):575-87. PubMed ID: 16098073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nephrotic syndrome associated with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Reddy P; Johnson K; Uberti JP; Reynolds C; Silver S; Ayash L; Braun TM; Ratanatharathorn V
    Bone Marrow Transplant; 2006 Sep; 38(5):351-7. PubMed ID: 16862167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk-factor analysis for predicting progressive- or quiescent-type chronic graft-versus-host disease in a patient cohort with a history of acute graft-versus-host disease after allogeneic stem cell transplantation.
    Sohn SK; Kim DH; Baek JH; Kim JG; Lee KB; Lee KH; Lee JH; Choi SJ; Lee JH; Shin IH
    Bone Marrow Transplant; 2006 Apr; 37(7):699-708. PubMed ID: 16501588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antineutrophil cytoplasmic antibodies (ANCA) in chronic graft-versus-host disease after allogeneic bone marrow transplantation.
    Martin SJ; Audrain MA; Oksman F; Ecoiffier M; Attal M; Milpied N; Esnault VL
    Bone Marrow Transplant; 1997 Jul; 20(1):45-8. PubMed ID: 9232255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association with the presence of naive T cells in chronic myeloid leukemia patients after allogeneic human stem cell transplantation and the lower incidence of chronic graft-versus host disease and relapse.
    Wysoczanska B; Bogunia-Kubik K; Dlubek D; Jaskula E; Sok A; Drabczak-Skrzypek D; Sedzimirska M; Lange A
    Transplant Proc; 2007 Nov; 39(9):2898-901. PubMed ID: 18022011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B-cell involvement in chronic graft-versus-host disease.
    Kapur R; Ebeling S; Hagenbeek A
    Haematologica; 2008 Nov; 93(11):1702-11. PubMed ID: 18728020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
    J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infectious complications in chronic graft-versus-host disease: a retrospective study of 145 recipients of allogeneic hematopoietic stem cell transplantation with reduced- and conventional-intensity conditioning regimens.
    Yamasaki S; Heike Y; Mori S; Fukuda T; Maruyama D; Kato R; Usui E; Koido K; Kim S; Tanosaki R; Tobinai K; Teshima T; Takaue Y
    Transpl Infect Dis; 2008 Jul; 10(4):252-9. PubMed ID: 18194371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
    Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
    Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis B virus reactivation with clinical flare in allogeneic stem cell transplants with chronic graft-versus-host disease.
    Seth P; Alrajhi AA; Kagevi I; Chaudhary MA; Colcol E; Sahovic E; Aljurf M; Gyger M
    Bone Marrow Transplant; 2002 Aug; 30(3):189-94. PubMed ID: 12189538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic graft-versus-host disease after allogeneic stem cell transplantation: challenges in prevention, science, and supportive care.
    Joseph RW; Couriel DR; Komanduri KV
    J Support Oncol; 2008; 6(8):361-72. PubMed ID: 19149321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation.
    Blau IW; Schmidt-Hieber M; Leschinger N; Göldner H; Knauf W; Hopfenmüller W; Thiel E; Blau O
    Ann Hematol; 2007 Aug; 86(8):583-9. PubMed ID: 17468869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Non-myeloablative allogeneic stem cell transplantation].
    Dalgaard J; Fløisand Y; Stenersen M; Egeland T; Brinch L
    Tidsskr Nor Laegeforen; 2007 Mar; 127(6):721-4. PubMed ID: 17363982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune modulation and chronic graft-versus-host disease.
    Soiffer R
    Bone Marrow Transplant; 2008 Aug; 42 Suppl 1():S66-S69. PubMed ID: 18724307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.